Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings [0.03%]
肌层浸润性膀胱癌新辅助、辅助和围手术治疗比较：网络 Meta 分析结果解释的临床和方法学考虑因素
Ronac Mamtani,Patrick Squires,Ali Mojebi et al.
Ronac Mamtani et al.
Serum levels of microRNA-371a-3p (M371) for prediction of histology in chemotherapy-naïve patients with testicular germ cell tumours undergoing lymph node dissection-a retrospective analysis of 57 cases [0.03%]
化疗初治睾丸生殖细胞肿瘤患者行淋巴结切除术前血清微小核糖核酸-371a-3p(M371)水平对病理分型的预测价值：一项回顾性分析研究(57例报告)
Klaus-Peter Dieckmann,Markus Angerer,Cansu Dumlupinar et al.
Klaus-Peter Dieckmann et al.
Background: Serum levels of microRNA-371a-3p (M371) represent a novel serum tumour marker of testicular germ cell tumours (GCTs). Little is known about its utility for assessing regional lymph nodes in chemotherapy-naïve...
Micro-ultrasound as an alternative to MRI in prostate cancer biopsy: Correlation with prostatectomy findings [0.03%]
微型超声作为前列腺癌活检的MRI替代方法与前列腺切除术结果相关性研究
Kira Furlano,Henning Plage,Nicolas Hertzsprung et al.
Kira Furlano et al.
Background: Accurate detection of clinically significant prostate cancer (csPCa) is essential for treatment decisions. MRI-targeted biopsy improves accuracy but is limited by cost, availability, and inter-reader variabili...
Deep and durable prostate-specific antigen response following comprehensive involved site radiotherapy for prostate cancer oligometastases [0.03%]
前列腺癌寡转移患者接受全面病灶区放疗后的深度且持久的前列腺特异性抗原反应
Megha Schmalzle,Muskaandeep Kaur,Rachel Radigan et al.
Megha Schmalzle et al.
Background and objective: Achieving undetectable prostate-specific antigen (PSA) has been correlated with improved outcomes for patients with metastatic prostate cancer. Comprehensive involved site radiotherapy (ISRT) con...
Tumor cell invasion in blood vessels but not lymphatic vessels in TURBT predicts poor prognosis in bladder cancer [0.03%]
经尿道膀胱肿瘤切除术后血液中肿瘤细胞浸润预测膀胱癌预后不良，而淋巴管中则不如此
Birgitte Carlsen,Tor Audun Klingen,Bettina Kulle Andreassen et al.
Birgitte Carlsen et al.
Background: Vessel invasion (VI) in transurethral resection of bladder tumor (TURBT) is associated with lymph node metastases and reduced survival. Separation of blood (BVI) and lymph (LVI) vessel invasion with immunohist...
Retraction notice to "microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes" [Urologic Oncology: Seminars and Original Investigations 33 (2015) 205.e1-205.e11] [0.03%]
有关“microRNA-107在肾透明细胞癌中的作用”一文的撤稿声明[Urologic Oncology: Seminars and Original Investigations 33 (2015) 205.e1-205.e11]
Nan Song,Xin Ma,Hongzhao Li et al.
Nan Song et al.
Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis [0.03%]
尿液肿瘤DNA诊断膀胱癌系统评价和网络meta分析
Shugo Yajima,Naoki Imasato,Tadayoshi Hashimoto et al.
Shugo Yajima et al.
Accurate, non-invasive detection of urothelial carcinoma (UC) remains an unmet clinical need. Urinary tumor DNA (utDNA) assays have recently emerged as promising tools, but their comparative diagnostic performance across assay types remains...
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions [0.03%]
膀胱癌的表观遗传特征和风险因素：对诊断和治疗干预的影响
Bhagyashree Pradhan,Prahallad Mishra,Pujarini Dash et al.
Bhagyashree Pradhan et al.
Within the broader urological landscape, bladder cancer (BC) continues to be a resilient malignancy, characterised by a burgeoning prevalence and an intricate etiological framework involving both genetic and environmental determinants. The ...
Partial gland ablation for radio-recurrent prostate cancer: Short-term oncological and functional outcomes [0.03%]
前列腺放疗复发后的部分腺体消融治疗的短期疗效及功能评估结果
Luis G Medina,Masatomo Kaneko,Lorenzo Storino Ramacciotti et al.
Luis G Medina et al.
Introduction and objective: To assess outcomes and complications of partial gland cryoablation (sCRYO) and high-intensity focused ultrasound (sHIFU) for localized radio-recurrent prostate cancer (CaP). ...